Physician profile
Kendra Considine
NPI 1609588110
$23,370.94
in general payments reported to CMS, 2019-2025
17 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,651 · 2024: $1,851 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,864 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,432 · Consulting Fee: $3,840 · Travel and Lodging: $3,223 · Education: $11.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,864.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,432.00 |
| Consulting Fee | $3,840.00 |
| Travel and Lodging | $3,223.23 |
| Education | $11.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14,743.83 | 2024-2025 | Cobenfy |
| Abbvie INC. | $1,531.14 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,207.19 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,051.74 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $784.24 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $651.31 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $650.29 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $584.64 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $521.95 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $492.54 | 2024-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $450.05 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Janssen Pharmaceuticals, INC | $250.42 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Corium, LLC | $216.24 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $137.63 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $54.19 | 2025 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $30.03 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $13.51 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Considine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.